Skip to content
Home/Companies/Biotech/Advesya
Advesya

Advesya

Biotech·France·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Advesya?

Advesya is a French Biotech company, currently owned by Jeito Capital since 2022.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Jeito Capital
Investor
Jeito Capital
Jeito I · 2021 · VC

Key facts

HQFrance
SectorBiotech
Websiteadvesya.com

More from Jeito I

Other portfolio companies in the same fund.

Corteria Pharmaceuticals
Corteria Pharmaceuticals
Active
BiotechFrance· 2023
Noema Pharma
Noema Pharma
Active
BiotechSwitzerland· 2023
CatalYm
CatalYm
Active
BiotechGermany· 2022
CDR-Life
CDR-Life
Active
BiotechSwitzerland· 2022
EyeBio
Exited 2024
BiotechUS· 2022
to Merck
NMD Pharma
NMD Pharma
Active
BiotechDenmark· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Advesya?

Advesya is currently owned by Jeito Capital, through Jeito I, since 2022.

When did Jeito Capital acquire Advesya?

Jeito Capital acquired Advesya in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue